Innovative Therapeutic
Devices Addressing
Significant Unmet Needs

About Us

Fibralign is an award-winning, Stanford-spinout company that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge® Collagen Matrix, which has been developed to address secondary lymphedema*, a global chronic disease that currently has no cure.

BioBridge® Collagen Matrix

  • Novel thread-like nanostructured surgical mesh for use in soft tissue repair
  • Clinical benefit demonstrated in treating secondary lymphedema*
  • CE mark approved, Class III device
  • FDA 510(k) cleared device*
  • Commercially available now in the US and Europe

Nanoweave® Technology

Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.

Grants, Awards, Partners and Collaborators

Fibralign has been recognized for its vision and potential to impact lives globally. We are supported in our mission by world class partners and collaborators.

Latest News

 

Fibralign Announces Strategic Partnership with Terumo

Fibralign Announces Strategic Partnership with Terumo

Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...

read more
Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...

read more
Fibralign receives ISO 13485:2016 upgrade certification

Fibralign receives ISO 13485:2016 upgrade certification

Fibralign received Certification Notification on January 21, 2019 from DEKRA Certification B. V. that the Company's management system meets the requirements of EN ISO 13486:2016. This internationally agreed standard sets out the requirements for a quality management...

read more

* BioBridge has not been approved by the FDA for treating secondary lymphedema.